Zurcher Kantonalbank Zurich Cantonalbank Sells 2,334 Shares of Qiagen NV (QGEN)
Zurcher Kantonalbank Zurich Cantonalbank decreased its holdings in Qiagen NV (NASDAQ:QGEN) by 3.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,800 shares of the company’s stock after selling 2,334 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Qiagen were worth $1,963,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also modified their holdings of the company. American International Group Inc. bought a new position in Qiagen in the fourth quarter worth approximately $154,000. Lourd Capital LLC bought a new position in Qiagen in the fourth quarter worth approximately $223,000. Forward Management LLC bought a new position in Qiagen in the first quarter worth approximately $309,000. Bronfman E.L. Rothschild L.P. raised its stake in Qiagen by 50.8% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 11,451 shares of the company’s stock worth $354,000 after buying an additional 3,860 shares in the last quarter. Finally, State of Alaska Department of Revenue bought a new position in Qiagen in the fourth quarter worth approximately $445,000. 62.23% of the stock is owned by institutional investors.
NASDAQ QGEN opened at $35.13 on Thursday. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69. Qiagen NV has a 12-month low of $34.89 and a 12-month high of $35.09.
Qiagen declared that its board has initiated a stock buyback program on Wednesday, January 31st that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.
A number of equities analysts recently commented on QGEN shares. Commerzbank reissued a “buy” rating on shares of Qiagen in a research note on Friday, January 19th. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research note on Monday, January 22nd. Goldman Sachs started coverage on shares of Qiagen in a research note on Monday, January 29th. They issued a “buy” rating and a $39.00 price objective for the company. Morgan Stanley boosted their price objective on shares of Qiagen from $38.00 to $39.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research raised shares of Qiagen from a “sell” rating to a “hold” rating in a research note on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $35.55.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.